naloxone

FDA approves Rextovy, a new 4mg over-the-counter naloxone nasal spray, expanding options for opioid overdose emergency response. What families need to know.

DEA Rocky Mountain Field Division warns of dangerous fentanyl pills mixed with carfentanil and heroin in Colorado and Utah. Alert covers clinical risks, naloxone use, and harm reduction guidance.

Boston reports 120 opioid overdose deaths in 2025—a 56% decline from 2023 peak and the lowest number in 10 years, driven by expanded naloxone access and harm reduction strategies.

CDC data shows nitazene-related overdose deaths surged from 27 in 2020 to 409 in 2024. Learn what families need to know about these dangerous synthetic opioids.

Rhode Island reports 219 overdose deaths in 2025, a 50% decline since 2022 and the lowest number in over a decade, surpassing the state's 2030 reduction goal.

Massachusetts achieves historic milestone as opioid-related overdose deaths drop to 978 in 2025 — a nearly 60% decline from the 2022 peak.

DEA identifies 5-chloro desmethyl chlorphine—a new class of ultra-potent synthetic opioids—in Tennessee seizure. Learn the risks and how to stay safe.

DEA issues urgent safety advisory as fentanyl is increasingly combined with xylazine, nitazenes, cychlorphine, and medetomidine—substances that can defeat standard overdose reversal.

CDC data shows overdose deaths dropped to under 70,000 in 2025 — the lowest since 2019. Alabama, New York, and Virginia see 25-30% declines, while Arizona and New Mexico experience alarming spikes.